PDE4A and chronic obstructive pulmonary disease: Taken all together, according to the completed RCTs, roflumilast was dramatically effective to patients with severe and profound COPD treated with ICS/LABA and notably reduced the incidence of exacerbation but brought PDE4 inhibitor-associated AEs.